CoChat
Sign Up
Cited by 50

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Antidepressant Withdrawal and Rebound Phenomena

Henssler, Jonathan, Heinz, Andreas, Brandt, Lasse, Bschor, Tom·2019·Deutsches Ärzteblatt international
DOI 10.3238/arztebl.2019.0355
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3238/arztebl.2019.0355

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 75

  1. Schwabe U, Ludwig WD: Arzneiverordnungen 2017 im Überblick. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J, eds.: Arzneiverordnungs-Report 2018. Berlin, Heidelberg: Springer 2018; 3–26 · DOI
  2. Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237–56.
  3. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63–71 · DOI · Paper page
  4. Michelson D, Amsterdam J, Apter J, et al.: Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000; 25: 169–77 · DOI
  5. Zajecka J, Fawcett J, Amsterdam J, et al.: Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18: 193–7 · DOI · Paper page
  6. Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505 · DOI
  7. Markowitz JS, DeVane CL, Liston HL, Montgomery SA: An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15: 329–33 · DOI · Paper page
  8. Kaufman MJ, Henry ME, Frederick B, et al.: Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 2003; 54: 534–9 · DOI
  9. Ninan PT, Musgnung J, Messig M, Buckley G, Guico-Pabia CJ, Ramey TS: Incidence and timing of taper/posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder. Prim Care Companion CNS Disord 2015; 17 · DOI
  10. Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W: Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin 2012; 28: 815–21 · DOI
  11. Giller E, Bialos D, Harkness L, Jatlow P, Waldo M: Long-term amitriptyline in chronic depression. Hillside J Clin Psychiatry 1985; 7: 16–33.
  12. Charney DS, Heninger GR, Sternberg DE, Landis H: Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982; 141: 377–86 · DOI
  13. Gahr M, Schonfeldt-Lecuona C, Kolle MA, Freudenmann RW: Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry 2013; 46: 123–9 · DOI
  14. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I: Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80 · DOI · Paper page
  15. Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT: Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol 2014; 34: 365–8 · DOI · Paper page
  16. Ellison JM: SSRI withdrawal buzz. J Clin Psychiatry 1994; 55: 544–5.
  17. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835–8 · DOI · Paper page
  18. Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC: Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011; 2: 159 · DOI · Paper page
  19. Harvey BH, Slabbert FN: New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 2014; 29: 503–16 · DOI
  20. Dilsaver SC, Feinberg M, Greden JF: Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983; 140: 249–51 CrossRef · DOI
  21. Beesdo K, Bittner A, Pine DS, et al.: Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 2007; 64: 903–12 · DOI · Paper page
  22. Boschloo L, Spijker AT, Hoencamp E, et al.: Predictors of the onset of manic symptoms and a (hypo) manic episode in patients with major depressive disorder. PLoS One 2014; 9: e106871 · DOI
  23. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. Psychother Psychosom 2002; 71: 195–9 · DOI · Paper page
  24. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA: Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998; 155: 1443–5 · DOI · Paper page
  25. Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D: Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res 2006; 40: 328–36 · DOI
  26. Hotopf M, Hardy R, Lewis G: Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120–7 · DOI
  27. Van Geffen EC, Brugman M, Van Hulten R, Bouvy ML, Egberts AC, Heerdink ER: Patients‘ concerns about and problems experienced with discontinuation of antidepressants. Int J Pharm Pract 2007; 15: 291–3 · DOI · Paper page
  28. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87 · DOI · Paper page
  29. Berber MJ: FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation). J Clin Psychiatry 1998; 59: 255 · DOI
  30. Hartford J, Kornstein S, Liebowitz M, et al.: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–74 · DOI
  31. Montgomery SA, Andersen HF: Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297–309 · DOI
  32. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207–12 · DOI
  33. Vandel P, Sechter D, Weiller E, et al.: Post‐treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol 2004; 19: 585–6 · DOI
  34. McGrath PJ, Stewart JW, Tricamo E, Nunes EN, Quitkin FM: Paradoxical mood shifts to euthymia or hypomania upon withdrawal of antidepressant agents. J Clin Psychopharmacol 1993; 13: 224–5 · DOI
  35. Tyrer P: Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord 1984; 6: 1–7 · DOI
  36. MacCall C, Callender J: Mirtazapine withdrawal causing hypomania. Br J Psychiatry 1999; 175: 390 · DOI
  37. Fauchere PA: Recurrent, persisting panic attacks after sudden discontinuation of mirtazapine treatment: a case report. Int J Psychiatry Clin Pract 2004; 8: 127–9 · DOI
  38. Berigan TR: Bupropion-associated withdrawal symptoms revisited: a case report. Prim Care Companion J Clin Psychiatry 2002; 4: 78 · DOI
  39. Mirin SM, Schatzberg AF, Creasey DE: Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry 1981; 138: 87–9 · DOI
  40. Rothschild AJ: Mania after withdrawal of isocarboxazid. J Clin Psychopharmacol 1985; 5: 340–2 · DOI
  41. Stoukides JA, Stoukides CA: Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991; 148: 1263 · DOI
  42. Sathananthan GL, Gershon S: Imipramine withdrawal: an Akathisia like syndrome. Am J Psychiatry 1973; 130: 1286–7 · DOI
  43. Goldstein TR, Frye MA, Denicoff KD, et al.: Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry 1999; 60: 563–7 · DOI
  44. Wolfe RM: Antidepressant withdrawal reactions. Am Fam Physician 1997; 56: 455–62.
  45. Reeves RR, Mack JE, Beddingfield JJ: Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy 2003; 23: 678–81 · DOI
  46. Cosci F, Chouinard G, Chouinard V-A, Fava GA: The diagnostic clinical interview for drug withdrawal 1 (DID-W1)–new symptoms of selective serotonin reuptake inhibitors (SSRI) or serotonin Norepinephrine reuptake inhibitors (SNRI): inter-rater reliability. Riv Psichiatr 2018; 53: 95–9.
  47. Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006; 13: e69–74.
  48. El-Mallakh RS, Briscoe B: Studies of long-term use of antidepressants. CNS Drugs 2012; 26: 97–109 · DOI · Paper page
  49. Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293–306 · DOI · Paper page
  50. Hohagen F, Montero RF, Weiss E, et al.: Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994; 244: 65–72 · DOI
  51. Hindmarch I, Kimber S, Cockle SM: Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15: 305–18 · DOI · Paper page
  52. Judge R, Parry MG, Quail D, Jacobson JG: Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17: 217–25 · DOI · Paper page
  53. Bogetto F, Bellino S, Revello RB, Patria L: Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16: 273–83 · DOI · Paper page
  54. Benmansour S, Altamirano AV, Jones DJ, et al.: Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol Psychiatry 2004; 55: 313–6 · DOI
  55. Kittler K, Lau T, Schloss P: Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol 2010; 629: 63–7 · DOI
  56. Mirza NR, Nielsen EØ, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 858–66 CrossRef · DOI
  57. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A: Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22: 6766–72 · DOI
  58. Klomp A, Hamelink R, Feenstra M, Denys D, Reneman L: Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS One 2014; 9: e99873 · DOI
  59. Montgomery D: ECNP consensus meeting March 2000. Guidelines for investigating efficacy in GAD. Eur Neuropsychopharmacol 2002; 12: 81–7 · DOI
  60. Amsden GW, Georgian F: Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 1996; 16: 684–6. · DOI · Paper page
  61. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA: Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14: 206–7 · DOI · Paper page
  62. Benazzi F: Fluoxetine for clomipramine withdrawal symptoms. Am J Psychiatry 1999; 156: 661–2. · DOI
  63. Giakas WJ, Davis JM: Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatr Ann 1997; 27: 85–92 · DOI
  64. Voderholzer U: Machen Antidepressiva abhängig?–Pro Psychiatr Prax 2018; 45: 344–5 · DOI
  65. Lichtigfeld FJ, Gillman MA: The possible abuse of and dependence on major tranquillisers and tricyclic antidepressants. S Afr Med J 1994; 84: 5–6.
  66. WHO: International Statistical Classification of Diseases and Related health problems, 10th revision, 5th edition,: World Health Organization; 2015.
  67. Bosman RC, Waumans RC, Jacobs GE, et al.: Failure to respond after reinstatement of antidepressant medication: a systematic review. Psychother Psychosom 2018; 87: 268–75 · DOI · Paper page
  68. Reidenberg MM: Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339: 324–8 · DOI · Paper page
  69. Reid JL, Campbell BC, Hamilton CA: Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension 1984; 6: II71–5 · DOI
  70. O‘Brien ET, MacKinnon J: Propranolol and polythiazide in treatment of hypertension. Br Heart J 1972; 34: 1042–4 · DOI
  71. Westermeyer J: Addiction to tranylcypromine (Parnate): a case report. Am J Drug Alcohol Abuse 1989; 15: 345–50 · DOI
  72. Griffin N, Draper RJ, Webb MG: Addiction to tranylcypromine. Br Med J (Clin Res Ed) 1981; 283: 346 · DOI
  73. Ainsworth K, Smith SE, Zetterström TS, Pei Q, Franklin M, Sharp T: Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl)1998; 140: 470–7 · DOI
  74. Heinz AJ, Beck A, Meyer-Lindenberg A, Sterzer P, Heinz A: Cognitive and neurobiological mechanisms of alcohol-related aggression. Nat Rev Neurosci 2011; 12: 400–13 · DOI · Paper page
  75. Hiemke C, Bergemann N, Clement HW, et al.: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62 · DOI

Cited by

Sorted by citations

See all 50

Metadata

Authors
Henssler, J., Heinz, A., Brandt, L., & Bschor, T.
Venue
Deutsches Ärzteblatt international
Publisher
Deutscher Arzte-Verlag GmbH
Published
2019-05-17
ISSN
1866-0452
DOI
10.3238/arztebl.2019.0355
Cited by
50
References
24

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant Withdrawal and Rebound Phenomena. https://app.cochat.ai/papers/10.3238/arztebl.2019.0355
The paper
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019). Antidepressant Withdrawal and Rebound Phenomena. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2019.0355